[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. https://doi.org/10.3322/caac.21590
|
[3]
|
Zhang, W., Zhang, B., He, J., Fan, J., Li, J., Zhang, B., et al. (2021) Clinicopathological Characteristics and Treatment of Young Women with Breast Cancer in China: A Nationwide Multicenter 10-Year Retrospective Study. Gland Surgery, 10, 175-185. https://doi.org/10.21037/gs-20-574
|
[4]
|
Li, J., Zhang, B., Fan, J., Pang, Y., Zhang, P., Wang, S., et al. (2011) A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Epidemiological Study of Female Breast Cancer in China. BMC Cancer, 11, Article No. 364. https://doi.org/10.1186/1471-2407-11-364
|
[5]
|
Desiris, K., Dragoumis, D., Assimaki, A. and Tsiftsoglou, A. (2012) 51 Very Young Women (<35 Years) with Primary Breast Cancer. A Single Institution Retrospective Analysis (2005-2009). European Journal of Cancer, 48, S55. https://doi.org/10.1016/s0959-8049(12)70119-3
|
[6]
|
Han, J., Jiang, Y., Zhang, C., Pang, D., Zhang, M., Wang, Y., et al. (2011) Clinicopathologic Characteristics and Prognosis of Young Patients with Breast Cancer. The Breast, 20, 370-372. https://doi.org/10.1016/j.breast.2011.02.011
|
[7]
|
Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., et al. (2002) Very Young Women (<35 Years) with Operable Breast Cancer: Features of Disease at Presentation. Annals of Oncology, 13, 273-279. https://doi.org/10.1093/annonc/mdf039
|
[8]
|
El Saghir, N.S., Seoud, M., Khalil, M.K., Charafeddine, M., Salem, Z.K., Geara, F.B., et al. (2006) Effects of Young Age at Presentation on Survival in Breast Cancer. BMC Cancer, 6, Article No. 194. https://doi.org/10.1186/1471-2407-6-194
|
[9]
|
Dubsky, P.C., Gnant, M.F.X., Taucher, S., Roka, S., Kandioler, D., Pichler-Gebhard, B., et al. (2002) Young Age as an Independent Adverse Prognostic Factor in Premenopausal Patients with Breast Cancer. Clinical Breast Cancer, 3, 65-72. https://doi.org/10.3816/cbc.2002.n.013
|
[10]
|
邬昊, 吕青. 全球及中国乳腺癌的流行病学趋势及防控启示: 2018-2022年《全球癌症统计报告》解读[J]. 中国普外基础与临床杂志, 2024, 31(7): 796-802.
|
[11]
|
Agarwal, G., Pradeep, P.V., Aggarwal, V., Yip, C. and Cheung, P.S.Y. (2007) Spectrum of Breast Cancer in Asian Women. World Journal of Surgery, 31, 1031-1040. https://doi.org/10.1007/s00268-005-0585-9
|
[12]
|
Kim, E., Noh, W.C., Han, W. and Noh, D. (2011) Prognostic Significance of Young Age (<35 Years) by Subtype Based on ER, PR, and HER2 Status in Breast Cancer: A Nationwide Registry‐Based Study. World Journal of Surgery, 35, 1244-1253. https://doi.org/10.1007/s00268-011-1071-1
|
[13]
|
Han, W., Kim, S.W., Ae Park, I., Kang, D., Kim, S., Youn, Y., et al. (2004) Young Age: An Independent Risk Factor for Disease-Free Survival in Women with Operable Breast Cancer. BMC Cancer, 4, Article No. 82. https://doi.org/10.1186/1471-2407-4-82
|
[14]
|
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., et al. (2018) Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. International Journal of Cancer, 144, 1941-1953. https://doi.org/10.1002/ijc.31937
|
[15]
|
Sopik, V. (2020) International Variation in Breast Cancer Incidence and Mortality in Young Women. Breast Cancer Research and Treatment, 186, 497-507. https://doi.org/10.1007/s10549-020-06003-8
|
[16]
|
Daly, A.A., Rolph, R., Cutress, R.I. and Copson, E.R. (2021) A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer. Breast Cancer: Targets and Therapy, 13, 241-257. https://doi.org/10.2147/bctt.s268401
|
[17]
|
Johnson, R.H., Anders, C.K., Litton, J.K., Ruddy, K.J. and Bleyer, A. (2018) Breast Cancer in Adolescents and Young Adults. Pediatric Blood & Cancer, 65, e27397. https://doi.org/10.1002/pbc.27397
|
[18]
|
Paluch-Shimon, S., Cardoso, F., Partridge, A.H., Abulkhair, O., Azim, H.A., Bianchi-Micheli, G., et al. (2020) ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology, 31, 674-696. https://doi.org/10.1016/j.annonc.2020.03.284
|
[19]
|
叶丹, 李勇, 林琅, 等. 年轻乳腺癌诊断延迟影响因素及现状[J]. 现代医药卫生, 2022, 38(9): 1540-1543.
|
[20]
|
赵津, 杨子佳. 年轻不是乳腺肿瘤“挡箭牌” [N].天津日报, 2024-12-24(011).
|
[21]
|
魏冬, 温静, 曾蓓蕾, 等. 炎症标志物与T1期乳腺癌预后因素分析及预测模型构建[J]. 四川医学, 2024, 45(2): 155-162.
|
[22]
|
汤婵丽, 李英, 章小飞. 术前中性粒细胞与淋巴细胞计数比值联合糖类抗原153对乳腺癌的诊断价值[J]. 中国妇幼保健, 2023, 38(2): 237-240.
|
[23]
|
程晓成, 卫翀羿, 柴效科, 等. 术前外周血红细胞分布宽度联合中性粒细胞/淋巴细胞比值在乳腺癌诊断中的临床价值[J]. 中国现代普通外科进展, 2023, 26(9): 703-708.
|
[24]
|
于艳艳, 张丽媛, 孟洁. 外周血NLR、PLR和SII对乳腺肿瘤的诊断价值[J]. 滨州医学院学报, 2024, 47(5): 430-432.
|
[25]
|
徐恩松, 左燕雨, 李英霞, 等. 外周血NLR、PLR、SII对进展期NSCLC患者化疗疗效的预测价值[J]. 实用癌症杂志, 2025, 40(3): 369-372.
|
[26]
|
谢兰兰, 李进, 朱奕, 等. 中性粒细胞/淋巴细胞比值与预后营养指数早期预测直肠癌术后吻合口漏的价值[J]. 腹腔镜外科杂志, 2022, 27(10): 758-762.
|
[27]
|
滕玥玥, 黄妙君, 黄胜超, 等. NLR、PLR、SII、LMR、CRP在乳腺癌患者血清中表达意义的研究进展[J]. 广东医科大学学报, 2024, 42(2): 203-208.
|
[28]
|
王坤英, 张蓬杰, 苏兵, 等. 乳腺癌患者血常规及PLR、NLR、LMR特征分析[J]. 检验医学与临床, 2022, 19(1): 84-89.
|
[29]
|
徐维琳, 周树, 唐金海, 等. 淋巴细胞/单核细胞比值在乳腺癌新辅助化疗疗效评估中的预测价值研究[J]. 中国肿瘤外科杂志, 2023, 15(1): 1-6.
|
[30]
|
Ni, X., Zhang, X., Ou-Yang, Q., Qian, G., Wang, L., Chen, S., et al. (2014) An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy. PLOS ONE, 9, e111886. https://doi.org/10.1371/journal.pone.0111886
|
[31]
|
王锋, 陈体, 刘金岭. MR影像组学相关指标与超声定量参数对乳腺癌患者NACT疗效的预测价值[J]. 实用癌症杂志, 2024, 39(11): 1811-1814.
|
[32]
|
Guo, Q., Dong, Z., Zhang, L., Ning, C., Li, Z., Wang, D., et al. (2017) Ultrasound Features of Breast Cancer for Predicting Axillary Lymph Node Metastasis. Journal of Ultrasound in Medicine, 37, 1354-1353. https://doi.org/10.1002/jum.14469
|
[33]
|
Lee, J.J., Jung, Y.L., Cheong, T., Espejo Valle-Inclan, J., Chu, C., Gulhan, D.C., et al. (2023) Erα-Associated Translocations Underlie Oncogene Amplifications in Breast Cancer. Nature, 618, 1024-1032. https://doi.org/10.1038/s41586-023-06057-w
|
[34]
|
Schally, A.V., Block, N.L. and Rick, F.G. (2017) Discovery of LHRH and Development of LHRH Analogs for Prostate Cancer Treatment. The Prostate, 77, 1036-1054. https://doi.org/10.1002/pros.23360
|
[35]
|
Hackshaw, A. (2009) Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in the Treatment of Breast Cancer. Expert Opinion on Pharmacotherapy, 10, 2633-2639. https://doi.org/10.1517/14656560903224980
|